The University of Sheffield announces approval of the first human trial testing regenerative cell therapy to treat sensorineural hearing loss, offering hope for restoring hearing function.
EU leaders are investigating why AstraZeneca are not following through with the pre-agreed number of vaccines for the Member States - taking a 60% cut to the expected amount.
The São Paulo Government and Butantan Institute revealed that the Sinovac COVID-19 vaccine is 15.6% less effective than officials previously suggested.
The projects will happen in 14 Member States and the United Kingdom, with 36 million in funding to get COVID-19 plasma to patients - boosting their immune response to the virus.
The approval of the Moderna COVID vaccine in the UK comes 2 days after European medical regulators, but not a moment too soon - the death toll continues to climb, standing at 78,508 currently.
Here, Mark Clements, MD PhD, paediatric endocrinologist, clinical investigator, and chief medical officer at Glooko Inc. takes part in a Q&A regarding his perspectives on remote clinical trials and data management tools.
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
Today (20 November) Pfizer and BioNTech are sending their drug for approval to the FDA, meaning that the most vulnerable Americans could get the vaccine in December.
New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
Yesterday, at 6:45am in the US, the Pfizer vaccine was revealed to be over 90% effective - so when will the successful drug be available for the UK to use?
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, China charts how to deal with dementia during the COVID-19 pandemic, starting with a helpful global and regional overview.
